- In May 2024, Regeneron Pharmaceuticals Inc. and Sanofi S.A. announced that the U.S. FDA approved Dupixent (dupilumab) for the treatment of prurigo nodularis in adults, making it the first and only biologic approved for this condition. This development marked a major milestone in the management of chronic inflammatory skin diseases, offering patients a targeted therapy that significantly reduces itch and nodule formation, thereby improving quality of life and setting a new standard in dermatologic care
- In April 2024, Galderma reported positive Phase III trial results for its investigational monoclonal antibody lebrikizumab, showing significant improvement in itch relief and nodule regression in prurigo nodularis patients. These results support the growing trend of targeting type 2 inflammation in chronic skin diseases and reinforce Galderma’s commitment to expanding biologic options in dermatology
- In February 2024, VYNE Therapeutics Inc. announced the initiation of a clinical trial to evaluate VYN201, a topical pan-bromodomain inhibitor, for the treatment of prurigo nodularis. This next-generation topical therapy aims to modulate gene expression involved in inflammation and skin thickening. The trial underscores the industry's focus on non-steroidal, localized treatments that offer improved safety profiles and efficacy for patients with refractory disease
- In January 2024, Incyte Corporation disclosed the start of a global Phase II study of ruxolitinib cream, a topical JAK inhibitor, in patients with prurigo nodularis. Given the success of JAK inhibitors in other dermatologic indications, this move reflects the expanding research into precision therapies for chronic pruritic conditions, with potential for both monotherapy and combination use
- In December 2023, the European Academy of Dermatology and Venereology (EADV) released updated clinical guidelines recognizing prurigo nodularis as a distinct and severely burdensome dermatological disease. The guidelines emphasize early diagnosis, stepwise treatment approaches, and inclusion of biologic and immunomodulatory therapies. This development highlights increasing clinical awareness and support for standardized, evidence-based treatment frameworks across Europe
